← Leaderboards
Andrew Rudd
Palm Therapeutics, Inc.
$526,101
Attributed
$1,052,201
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $590.8K · FY2020–22$1M$750K$500K$250K$0
'20
'21
'22
Funding mix
By agency
NIH$1,052,201 · 2
By mechanism
R43$1,052,201 · 2
Top collaborators
- Neal Krishna Devaraj4 shared
Others in their field
Other Emerging Leaders on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
Research focus
LeadMissionIn VitroJointsLipidsLipophilicityCouplingInnovationIn Vivo EvaluationCommercializationApoptosisDrug DevelopmentBaseDoseCollectionChemistryBindingFoundationsCell LineIn VivoBiologyCellsCell SurvivalPalmitoylation
Grant awards (4)
Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma$61,500
R43 · FY2022 · CA · contact PI
A Small Molecule Enzyme Replacement for the Treatment of CLN1$467,091
R43 · FY2021 · NS · contact PI
Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma$123,722
R43 · FY2021 · CA · contact PI
Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma$399,888
R43 · FY2020 · CA · contact PI